TAK (Takeda Pharmaceutical Co) Owner Earnings per Share (TTM): 0.28 (As of Jun. 2026) — 98% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TAK Takeda Pharmaceutical Co Ltd TAK
77 GF Score
Price $17.63
GF Value $14.24
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Owner Earnings per Share (TTM)?

Takeda Pharmaceutical Co TAK +1.38% 77 Owner Earnings per Share (TTM) is 0.28 as of Jun. 2026, which is 98% below its 10-year median of 12.84. GuruFocus rates TAK with a GF Score™ of 77/100 and a GF Value™ of $14.24 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 465 Drug Manufacturers companies, Takeda Pharmaceutical Co ranks worse than 80.65% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) ended in Jun. 2026 was $0.28. It's Price-to-Owner-Earnings ratio for today is 62.96.


The historical rank and industry rank for Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) or its related term are showing as below:

TAK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.66   Med: 12.84   Max: 64.49
Current: 63.03


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Takeda Pharmaceutical Co was 64.49. The lowest was 4.66. And the median was 12.84.


TAK's Price-to-Owner-Earnings is ranked worse than
80.65% of 465 companies
in the Drug Manufacturers industry
Industry Median: 23.87 vs TAK: 63.03

Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $0.22. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.34. It's PE Ratio (TTM) ratio for today is At Loss.

Takeda Pharmaceutical Co's EPS without NRI for the three months ended in Jun. 2026 was $0.22. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.34. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Related Terms


Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.16 1.86 0.47 1.16 0.39

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.05 0.95 0.39 0.28

TAK vs ZTS, UTHR: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Price-to-Owner-Earnings falls into.


TAK
77GF Score
Takeda Pharmaceutical Co Ltd TAK
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -1,033
Depreciation, Depletion and Amortization 4,333
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 2,656
Change In Working Capital 0
Shares Outstanding (Diluted Average) 3,209

1. Start with "Net Income" from income statement. Takeda Pharmaceutical Co's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-1,033 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Takeda Pharmaceutical Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was $4,333 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Takeda Pharmaceutical Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was $0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $2,656 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Takeda Pharmaceutical Co's 5-Year Average Maintenance Capital Expenditure = $2,656 Mil

5. "Change In Working Capital" is from cashflow statement. Takeda Pharmaceutical Co's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was $0 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Takeda Pharmaceutical Co's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 3209.441 Mil.

Takeda Pharmaceutical Co's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -1033.065 +4332.848+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-2655.8044373489+0)/3209.441
=0.28

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=17.63/0.28
=62.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.28 mean?
Takeda Pharmaceutical Co (TAK) has a Owner Earnings per Share (TTM) of 0.28 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Takeda Pharmaceutical Co. This is 98% below median its historical median of 12.84. Over the past decade, Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) has ranged from 4.66 to 64.49. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #375 out of 465 companies in the Drug Manufacturers industry, placing it in the top 80.6%.
Is Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) too high?
Takeda Pharmaceutical Co's current Owner Earnings per Share (TTM) of 0.28 is 98% below median its 10-year median of 12.84. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 64.49. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.87. Takeda Pharmaceutical Co's value of 0.28 is 98.8% below this industry median. Based on the distribution chart, Takeda Pharmaceutical Co ranks #375 out of 465 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Takeda Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #375 out of 465 companies for Owner Earnings per Share (TTM). This places Takeda Pharmaceutical Co in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.87. Takeda Pharmaceutical Co's value of 0.28 is 98.8% below this benchmark. Historically, Takeda Pharmaceutical Co's own Owner Earnings per Share (TTM) has ranged from 4.66 to 64.49 over the past decade. While the company's 10-year median is 12.84 vs. the industry median of 23.87, Takeda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.87, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takeda Pharmaceutical Co's current Owner Earnings per Share (TTM) of 0.28 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Takeda Pharmaceutical Co. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takeda Pharmaceutical Co's current Owner Earnings per Share (TTM) is 0.28, which is 98% below median its own 10-year median of 12.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.24, compared to a current price of $17.63 — trading 23.8% above its estimated fair value. The current Owner Earnings per Share (TTM) is 0.28, which is 98% below median its 10-year median of 12.84 and 98.8% below the Drug Manufacturers industry median of 23.87. Takeda Pharmaceutical Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current Owner Earnings per Share (TTM) is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $17.63 is trading 23.8% above its estimated GF Value™ of $14.24. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TAK:

  • Owner Earnings per Share (TTM): 0.28 (98% below median its 10-year median of 12.84)
  • GF Value™: $14.24 vs. price of $17.63 (23.8% above fair value)
  • GF Score™: 77/100 with 10 warning signs
  • Industry Position: 98.8% below the Drug Manufacturers median (#375 of 465)

No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
77GF Score

Get the complete analysis for TAK

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.63
Price
$14.24
GF Value